{'fraction_non_alphanumeric': 0.03643724696356275, 'fraction_numerical': 0.02699055330634278, 'mean_word_length': 5.102880658436214, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
aFGF immunoreactivity in prostate cancer and its co‐localization with bFGF and FGF8

Fibroblast growth factors (FGFs) have been implicated in the development of numerous malignancies including prostate cancer. In a pilot study it has been shown that FGF8 mRNA is up‐regulated in prostate cancer. The aim of the present study was to determine whether aFGF and bFGF were co‐expressed with FGF8 in human prostate cancer. Twenty‐nine cases of prostate cancer of different histological grades were examined. Immunohistochemical analysis was employed to study aFGF and bFGF expression. In the light of the results, aFGF immunoreactivity was studied in a further 43 cases. aFGF and bFGF immunoreactivity was identified in the cytoplasm of the malignant prostatic epithelium. aFGF was overexpressed in 62/72 (86·1 per cent) cases and bFGF in 19/29 (65·5 per cent). High levels of aFGF immunoreactivity were noted in areas of high‐grade prostatic intraepithelial neoplasia (PIN). In this series, aFGF immunoreactivity was most commonly observed and correlated closely with Gleason score and tumour stage ( p=0·007 and 0·007, respectively). Co‐localization of aFGF, bFGF, and FGF8 was detected in 9/29 (31·0 per cent) cases. There was a significant correlation between aFGF and FGF8 expression. In conclusion, aFGF, bFGF, and FGF8 are co‐localized in human prostate cancer; they may have a synergistic effect in prostate cancer growth and progression. Copyright © 1999 John Wiley & Sons, Ltd.